Aside from direct visualiztion of the coronary artery tree, there is no reliable test to determine patient risk for coronary artery disease (CAD). Mantis BioLogics developed a rapid, precise and cost-effective means of determining CAD risk. Automation of this process will enable screening of approximately 110 million patients annually, far more reliably than current methods allow, with an estimated annual market of over $1B.